• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by PolarityTE Inc.

    8/15/23 4:40:32 PM ET
    $PTE
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PTE alert in real time by email
    NT 10-Q 1 nt10-q.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    FORM 12b-25

     

    NOTIFICATION OF LATE FILING

     

    (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR

     

    For Period Ended: June 30, 2023

    ☐ Transition Report on Form 10-K

    ☐ Transition Report on Form 20-F

    ☐ Transition Report on Form 11-K

    ☐ Transition Report on Form 10-Q

     

    For the Transition Period Ended:

     

    Read Instruction (on back page) Before Preparing Form. Please Print or Type.

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

     

    PART I-REGISTRANT INFORMATION

     

    PolarityTE, Inc.
    Full name of Registrant
     
    N/A
    Former name if Applicable
     
    1960 S. 4250 West
    Address of Principal Executive Office (Street and number)
     
    Salt Lake City, UT 84104
    City, State and Zip Code

     

     

     

     

     

     

    PART II-RULE 12b-25 (b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

     

    ☐ (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
       
    (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, FORM N-CEN or Form N-CSR, or portion thereof will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
       
    (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

    PART III - NARRATIVE

     

    State below in reasonable detail why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    PolarityTE, Inc. (the “Company”) is filing this Notification of Late Filing on Form 12b-25 with respect to its Annual Report on Form 10-Q for the quarter ended June 30, 2023 (the “Form 10-Q”). The Company has determined that it is unable to file its Form 10-Q within the prescribed time period or within the five day extension period without unreasonable effort or expense for the reasons set forth below.

     

    As previously disclosed, on June 6, 2023, the Company together with certain of its subsidiaries (collectively, the “Debtors”) filed voluntary petitions for relief under Chapter 11 of 11 U.S.C. §§ 101 et seq. of the United States Code (the “Bankruptcy Code”) in the United States Bankruptcy Court for the District of Utah (the “Bankruptcy Court”) under the captions In re PolarityTE, Inc., a Delaware corporation (Case No. 23-bk-22358-KRA) (Bankr. D. Utah), In re PolarityTE, MD Inc., a Nevada corporation (Case No. 23-bk-22360-KRA) (Bankr. D. Utah), and In re PolarityTE, Inc., a Nevada corporation (Case No. 23-bk-22361-KRA) (Bankr. D. Utah) (collectively, the “Chapter 11 Cases”). The Debtors have filed a motion with the Bankruptcy Court seeking joint administration under the caption In re PolarityTE, Inc., a Delaware corporation (Case No. 23-bk-22358-KRA) (Bankr. D. Utah). On June 6, 2023, prior to the filing of the Chapter 11 Cases, the Debtors entered into a “stalking horse” asset purchase agreement (the “Asset Purchase Agreement”) with Grander Acquisition LLC, a Delaware limited liability company (“Grander Acquisition”), pursuant to which Grander Acquisition agreed to purchase substantially all of the assets of the Debtors for approximately $6.5 million, less the amount of debtor-in-possession financing outstanding at closing, if any, subject to certain exceptions, and plus the assumption of assumed liabilities.

     

    On July 26, 2023, the Debtors and Grander Acquisition entered into an amendment of the Asset Purchase Agreement (the “Amendment”). The Amendment updates certain lists of contracts and receivables subject to purchase by Grander Acquisition, updates certain sections of the disclosure schedules and revises the closing deadline to no later than the later of (i) the second business day after satisfaction or waiver of all conditions to closing and (ii) August 15, 2023. The Asset Purchase Agreement as amended by the Amendment is hereinafter referred to as the “Purchase Agreement.”

     

    2
     

     

    On July 31, 2023, the Bankruptcy Court entered an order (the “Sale Order”) approving and authorizing the acquisition of substantially all of the assets of the Debtors, including the assignment and assumption of certain contracts, as provided for in the Purchase Agreement.

     

    On August 15, 2023, the Debtors and Grander Acquisition consummated the transactions contemplated by the Purchase Agreement, thereby completing the disposition of substantially all of the Debtors’ assets in accordance with the Purchase Agreement.

     

    Due to the considerable time and resources that management has had to devote to the Chapter 11 Cases, the Sale Order and sale of the Debtors’ assets under the Purchase Agreement, and related obligations, and changes in the Company’s financial position, which would need to be reflected in the Company’s financial statements, the Company does not have the resources or personnel necessary to, without unreasonable effort or expense, timely file the Form 10-Q. At this time, the Company cannot estimate when it will be able to file the Form 10-Q, if at all.

     

    The Company cautions that trading in the Company’s securities during the pendency of the Chapter 11 Case is highly speculative and poses substantial risks. Trading prices for the Company’s securities may bear little or no relationship to the actual recovery, if any, by holders of the Company’s securities in the Chapter 11 Case.

     

    PART IV - OTHER INFORMATION

     

    (1) Name and telephone number of person to contact in regard to this notification.

     

    Jacob Patterson   435   640-6206
    (Name)   (Area Code)   (Telephone Number)

     

    (2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). ☒ Yes ☐ No

     

    (3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☒ Yes ☐ No

     

    If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    The Company’s results of operations for the quarter ended June 30, 2023 differed significantly from its results of operations for the quarter ended June 30, 2022 due to adverse developments that occurred with respect to the Company’s business and liquidity, including events precipitating the Company commencing the Chapter 11 Cases.

     

    3
     

     

    PolarityTE, Inc.

     

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: August 15, 2023 By: /s/ Jacob Patterson
        Jacob Patterson
        Chief Financial Officer

     

    4

    Get the next $PTE alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PTE

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PTE
    SEC Filings

    See more
    • PolarityTE Inc. filed SEC Form 8-K: Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits

      8-K - POLARITYTE, INC. (0001076682) (Filer)

      8/18/23 4:54:40 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form NT 10-Q filed by PolarityTE Inc.

      NT 10-Q - POLARITYTE, INC. (0001076682) (Filer)

      8/15/23 4:40:32 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

      8-K - POLARITYTE, INC. (0001076682) (Filer)

      8/15/23 4:30:36 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $PTE
    Leadership Updates

    Live Leadership Updates

    See more
    • PolarityTE Announces Entry Into a Letter of Intent For Acquisition of the Company

      SALT LAKE CITY, Dec. 27, 2022 /PRNewswire/ --  PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials (the "Company"), today announced that it signed a non-binding letter of intent (the "LOI") with Michael Brauser ("Brauser") for him to make an offer to acquire 100% of the outstanding equity interests of the Company at a proposed offering price of $1.03 per common share, which would be paid entirely in cash. As of December 23, 2022, there were 7,256,786 shares of the Company's common stock outstanding and unvested restricted stock units covering an additional 256,457 common shares. 

      12/27/22 8:30:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Reports Third Quarter 2022 Financial Results and Provides Business Update

      SALT LAKE CITY, Nov. 10, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended September 30, 2022. Recent Business and Financial UpdatesAt the end of April 2022, PolarityTE began enrollment in its Phase III randomized controlled trial (RCT), which is a pivotal study under its open IND for SkinTE®. The Company estimates that it may be able to complete enrollment of 100 subjects sometime in the first six mon

      11/10/22 4:30:00 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Confirms Receipt of Unsolicited, Non-Binding Offer to Acquire the Company

      SALT LAKE CITY, Nov. 9, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE), a biotechnology company developing regenerative tissue products and biomaterials, today confirmed that on November 1, 2022, it received an unsolicited, non-binding offer (followed by an amended offer on November 8, 2022) from Michael Brauser to acquire all of the outstanding common stock of the Company not owned by him for $1.25 per share in cash. The offer is subject to various contingencies, including, among others, (1) settlement with warrant holders and satisfactory negotiations with insiders with change of control agreements, (2) minimum tender conditions, (3) a sixty-day due diligence period, and (4) satisfacti

      11/9/22 8:00:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE Announces Resignation of Jeff Dyer from its Board of Directors

      SALT LAKE CITY, Sept. 8, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today announced that Jeff Dyer, PhD, has decided to resign from its Board of Directors, effective immediately. "On behalf of our Board and PolarityTE's management team, we thank Jeff for his service and longstanding commitment to the Company," stated Richard Hague, Chief Executive Officer of PolarityTE.  "We greatly appreciate the leadership and insight that Jeff has provided over the past five and a half years as we purs

      9/8/22 8:30:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Ambrx Appoints Audit Executive Chris Nolet to Board of Directors

      SAN DIEGO--(BUSINESS WIRE)--​Ambrx, a clinical stage biopharmaceutical company using an expanded genetic code to create Engineered Precision Biologics, today announced the appointment of Chris Nolet to the company’s Board of Directors. Mr. Nolet brings extensive experience as a long-time audit partner and business advisor in the life sciences industry, and has assumed the role of Chair of Ambrx’s Audit Committee. “We are delighted that Chris will be joining our Board of Directors given his deep expertise, knowledge base and industry network,” said Feng Tian, Ph.D., President and CEO of Ambrx. “His experience in helping transition clinical stage companies into commercially integra

      2/23/21 4:05:00 PM ET
      $VIE
      $PTE
      $RVNC
      Major Pharmaceuticals
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Biotechnology: Pharmaceutical Preparations

    $PTE
    Financials

    Live finance-specific insights

    See more
    • PolarityTE Reports Second Quarter 2022 Financial Results and Provides Business Update

      PolarityTE to host conference call and webcast today, August 11, 2022, at 4:30 p.m. ET SALT LAKE CITY, Aug. 11, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) a biotechnology company developing regenerative tissue products and biomaterials, today provided a business update and reported financial results for the quarterly period ended June 30, 2022. Recent Business and Financial UpdatesIn January 2022, PolarityTE was advised by the U.S. Food and Drug Administration (FDA) that it could conduct human clinical trials under PolarityTE's investigational new drug application (IND

      8/11/22 4:05:00 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • PolarityTE to Report Q2 2022 Financial Results on August 11, 2022

      SALT LAKE CITY, Aug. 1, 2022 /PRNewswire/ -- PolarityTE, Inc. (NASDAQ:PTE) today announced that it will report results for the quarter ended June 30, 2022, by press release on Thursday, August 11, 2022, at approximately 4:05 p.m. Eastern Time. In addition, the Company will host a conference call and webcast with Q&A on August 11, 2022, at 4:30 p.m. Eastern Time. The conference call can be accessed by calling 1-800-207-0148 with passcode 893469 and referencing "PolarityTE Second Quarter 2022 Business Update and Financial Results." A webcast of the conference call can be accesse

      8/1/22 8:00:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Polarity TE spins off IBEX Preclinical Research contract research organization

      Dr. Josh Packer acquires IBEX and becomes CEO; maintains existing surgical research team LOGAN, Utah, May 26, 2022 /PRNewswire-PRWeb/ -- IBEX Preclinical Research, Inc., a trusted outsourcing partner and provider of preclinical surgical and toxicological studies in a variety of laboratory animal species, announced that it has been acquired by Josh Packer, DVM. IBEX provides in-vivo research services ranging from relatively simple single-dose pharmacokinetic studies to more complex projects requiring surgical instrumentation. Conducting both GLP and non-GLP non-clinical testing, IBEX supports life science, medical device companies and researchers that specialize in orthopedics, neurosurgical,

      5/26/22 11:15:00 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by PolarityTE Inc. (Amendment)

      SC 13G/A - POLARITYTE, INC. (0001076682) (Subject)

      2/14/23 11:11:43 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by PolarityTE Inc.

      SC 13G - POLARITYTE, INC. (0001076682) (Subject)

      8/23/22 11:30:24 AM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed

      SC 13G - POLARITYTE, INC. (0001076682) (Subject)

      2/16/21 5:19:31 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PTE
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Dyer Jeffrey Hansen was granted 42,986 shares, increasing direct ownership by 3,177% to 44,339 units

      4 - POLARITYTE, INC. (0001076682) (Issuer)

      1/30/23 4:30:42 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 3: New insider Dyer Jeffrey Hansen claimed ownership of 1,353 shares

      3 - POLARITYTE, INC. (0001076682) (Issuer)

      1/30/23 4:15:33 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Nolet Chris decreased direct ownership by 72% to 14,403 units

      4 - POLARITYTE, INC. (0001076682) (Issuer)

      1/17/23 4:30:29 PM ET
      $PTE
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care